Company profile: Ascendis Pharma
1.1 - Company Overview
Company description
- Provider of the TransCon prodrug technology platform, which transiently conjugates an inert carrier to a parent drug for systemic or localized release, and a pipeline of investigational therapies: TransCon hGH for growth hormone deficiency, TransCon PTH for hypoparathyroidism, TransCon CNP for achondroplasia, and oncology candidates TransCon TLR7/8 Agonist and TransCon IL-2 β/γ.
Products and services
- TransCon hGH: Investigational therapy for growth hormone deficiency that predictably replaces missing hormones and extends their duration of action to optimize outcomes
- TransCon PTH: Prodrug-based therapy for hypoparathyroidism that restores physiologic parathyroid hormone levels to manage symptoms and complications in affected patients
- TransCon Technology: Innovative platform that engineers transient conjugation of an inert carrier to a parent drug, enabling systemic or localized release to optimize therapeutic effects across drug classes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ascendis Pharma
PharmAkea
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D, developing high-quality small molecule drug candidates against protein targets involved in fibroproliferative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmAkea company profile →
Arena Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cardiovascular, central nervous system, inflammatory, and metabolic diseases, including the development of lorcaserin hydrochloride, which has reported positive clinical trial data. Headquartered in San Diego, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arena Pharmaceuticals company profile →
Prismic Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel prescription medical drugs for inflammatory diseases and prescription medical foods for the clinical dietary management of metabolic processes associated with disorders common in the aging 'baby boomer' population, including central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prismic Pharmaceuticals company profile →
DiaMedica Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on treatments for stroke, developing DM199, a recombinant human tissue kallikrein-1 (KLK1) intended to treat acute ischemic stroke and cardio-renal diseases by restoring KLK1 levels, and conducting the ReMEDy2 adaptive, randomized, double-blind, placebo-controlled trial to study DM199’s efficacy and safety in acute ischemic stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DiaMedica Therapeutics company profile →
Glycotope
HQ: Germany
Website
- Description: Provider of GMP-compliant contract manufacturing for active biopharmaceutical ingredients (proteins and antibodies) via recombinant production, and oncology antibody solutions including GT-001 (Lewis Y), GT-002 (LYPD3), GT-00A (MUC1) and an IL-15 immuno-cytokine, plus GlycoTarget Discovery and a platform enabling high tumor-specificity by targeting tumor-associated carbohydrates for ADC/CAR development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycotope company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ascendis Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ascendis Pharma
2.2 - Growth funds investing in similar companies to Ascendis Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ascendis Pharma
4.2 - Public trading comparable groups for Ascendis Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →